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Abstract Intrinsic subtypes are widely accepted for the
classification of breast cancer. Lacking gene expression
data, surrogate classifications based on immunohistochem-
istry (IHC) have been proposed. A recent St. Gallen con-
sensus meeting recommends to use this ‘‘surrogate intrinsic
subtypes’’ for predicting adjuvant chemotherapy resistance,
implying that ‘‘Surrogate Luminal A’’ breast cancers should
only receive endocrine therapy. In this study we assessed
both gene expression based intrinsic subtypes as well as
surrogate intrinsic subtypes regarding their power to predict
neoadjuvant chemotherapy benefit. Single institution data of
560 breast cancer patients were reviewed. Gene expression
data was available for 247 patients. Subtypes were deter-
mined on the basis of IHC, Ki67, histological grade, endo-
crine responsiveness, and gene expression, and were
correlated with chemotherapy response and recurrence-free
survival. In ER?/HER2- tumors, a high histological grade
was the best predictor for chemotherapy benefit, both in
terms of pCR (p = 0.004) and recurrence-free survival
(p = 0.002). The gene expression based and surrogate
intrinsic subtype based on Ki67 had no predictive or prog-
nostic value in ER?/HER2- tumors. Histological grade,
ER, PR, and HER2 were the best predictive factors for
chemotherapy response in breast cancer. We propose to
continue the conventional use of these markers.
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Introduction
Breast cancer can be divided into different subtypes, based on
immunohistochemical (IHC) marker expression or on gene
expression array data. IHC-markers are routinely used in most
diagnostic labs. Hormone receptor status is used for the
assignment of endocrine therapy, whereas HER2
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overexpression identifies tumors sensitive to trastuzumab.
The intrinsic subtypes based on gene expression analysis, first
defined by Sorlie et al. [1] in 2001, have also gained wide
spread acceptance as a way of classifying breast cancer
tumors. Since gene expression data is often not available,
approximations of intrinsic subtypes based on routinely
available tests have been proposed. Recently, the expert panel
of the St. Gallen meeting [2] proposed to classify tumors for
therapeutic purposes based on such ‘‘surrogate intrinsic sub-
types’’. Luminal A disease (characterized by a positive hor-
mone receptor, absence of HER2 amplification and ‘‘low’’
Ki67 [\14 %]) is stated to require only endocrine therapy,
whereas in Luminal B/HER2-, Luminal B/HER2?, HER2-
enriched and triple negative disease, chemotherapy should be
considered. In case of HER2 amplification, trastuzumab
should be considered as well. For the ER?/HER2- tumors,
the new surrogate intrinsic subtype classification replaces the
concept of endocrine responsiveness, which was proposed at
the St. Gallen 2007 meeting [3] to separate the ER?/HER2-
tumors in a chemotherapy-sensitive and a chemotherapy-
resistant subgroup.
Recently, a large analysis of the German breast group
has focused on these surrogate intrinsic subtypes and
chemotherapy responses in an attempt to establish the
association between pCR and survival for each of the dif-
ferent subtypes [4]. This analysis suggested that it is
important to divide a breast cancer dataset according to
subtypes, as the relation between pCR and survival
depended strongly on the subtype. pCR was a suitable
surrogate end point for patients with luminal B/HER2-,
HER2?, and triple-negative disease but not for tumors
with luminal B/HER2? or luminal A tumors. Also, another
study applied the surrogate definitions to define different
prognostic breast cancer groups [5]. However, no gene
expression data were available in both studies, so the
association between the original gene expression based
classification, the surrogate intrinsic subtypes and chemo-
therapy response could not be established.
In this study, we compared the power to predict neo-
adjuvant chemotherapy response of gene expression based
intrinsic subtypes, as well as surrogate intrinsic subtype
definitions. Therefore, surrogate intrinsic subtypes were
determined in 560 patients and response and survival
analysis were performed. PAM50 gene expression based
intrinsic subtypes were available for 247 tumors.
Patients and methods
Patients
Pre-treatment biopsies of 560 primary breast tumors were
collected. All patients had received neoadjuvant treatment
at the Netherlands Cancer Institute between 2004 and 2012
as part of ongoing clinical trials, or were treated off pro-
tocol according to the standard arms of one of these stud-
ies. The studies had been approved by the ethical
committee and informed consent was obtained from all
patients. All tumors were either at least 3 cm in size, or the
presence of—axillary lymph node metastases had been
proven by fine needle aspiration (FNA). Biopsies were
taken using a 14 G core needle under ultrasound guidance.
After collection, specimens were snap-frozen in liquid
nitrogen and stored at -80 C. Each patient had two or
three biopsies taken to ensure that enough tumor material
was available for both diagnostics and research purposes.
Depending on the particular study, a treatment regimen
was assigned to each patient, which, for HER2-negative
tumors, consisted of one of the following: (1) six courses of
dose-dense Doxorubicin/Cyclophosphamide (ddAC); (2)
six courses of Capecitabine/Docetaxel (CD) or (3) if the
therapy response was considered ‘‘unfavorable’’ by MRI
evaluation [6] after three courses, ddAC was changed to
CD or vice versa. Study results have not been published
yet. However, a first analysis shows that switching of
chemotherapy regimen may be beneficial for initial non-
responding tumors (manuscript in preparation, de Rigter
et al.). pCR rates are not significantly different for patients
treated with AC or DC. All HER2? patients were treated
by a regimen of three cycles of 8-weekly courses of pac-
litaxel, trastuzumab, and carboplatin. Hormone receptor
positive patients received both chemotherapy and endo-
crine therapy.
Response evaluation
The pathological response in the resection specimen after
chemotherapy was used as an endpoint. Patients with a
complete absence of invasive tumor cells (irrespective of
carcinoma in situ) in the surgical specimen of the breast
and of the lymph nodes were considered to have a patho-
logical complete remission (pCR). All other patients (par-
tial and non responses) were included in the ‘‘no pCR’’
category.
Pathology
All tissue sections were reviewed by a consultant breast
cancer pathologist (J.W.) for histological classification and
immunohistochemical assessment. Samples were scored as
positive for ER and/or PR by immunohistochemistry
(IHC), when at least 10 % of the tumor cells nuclei showed
staining of the ER or PR, respectively. A sample was
scored as being HER2 positive when either a strong
membrane staining (3?) could be observed by IHC or if
CISH revealed amplification of HER2 in samples with
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moderate (2?) membrane staining at IHC. Ki67 staining
was performed with the MIB1 antibody (Dako, Glostrup,
Denmark), dilution 1:250. In another study by our group
(manuscript in preparation Rigter et al.) we assessed the
best Ki67 cut-off to differentiate Luminal A and Luminal B
tumors in our tumor set (Supplementary Fig. 1). We found
that the 95 % confidence interval ranged from 10 to 15 %.
14 % was then taken as a cut-off between low and high
proliferation index, as this cut-off was also described by
Cheang et al. [7]. For surrogate intrinsic subtyping based
on grade, grade 1 and 2 were combined into the low pro-
liferative group and grade 3 represented the high prolifer-
ative tumors.
For ER?/HER2- tumors, we determined the endocrine
responsiveness, as was described by Colleoni et al. [8].
Tumors were classified as highly endocrine responsive
when ER and PR were positive in at least 50 % of the cells
and incompletely endocrine responsive when either ER or
PR was positive in less than 50 % of the cells. Table 1
summarizes all different subtype definitions used in this
study.
Gene expression data
mRNA isolation and extraction from the frozen material
were performed, as described previously [9]. In short, a
5-lm section halfway through the biopsy was stained for
hematoxylin and eosin and analyzed by a pathologist for
tumor percentage. Only samples that contained at least
60 % tumor cells were subsequently analyzed on a
microarray. All samples were labeled and hybridized to
Illumina 6v3 arrays (Illumina, La Jolla, CA), according to
the manufacturer’s protocol. Data were log2 transformed
and between-array normalized using simple scaling. The
subtype single sample predictor ‘‘PAM50’’ [10] was used
to assign a molecular subtype to the samples based on their
expression profiles across the intrinsic gene set. In short,
the intrinsic genes were selected from the Illumina 6v3
platform, when a single gene was represented by multiple
probes the probe with the highest variance was chosen.
Subsequently, for all samples the Spearman correlation of a
sample (i.e., the expression of the intrinsic genes of that
sample) to the centroid of each corresponding molecular
subtype was calculated. Each sample was then assigned to
the subtype with the highest correlation.
Statistics
The Fisher’s exact test was used to assess associations
between the dichotomized response measures, pathological
and molecular markers. Survival curves were constructed
using the Kaplan–Meier technique, and survival was
compared using log rank tests. Multivariate analysis for
chemotherapy response (pCR) and cox-regression models
for recurrence free survival were performed to correct for
age, T- and N-stage. The contribution of the intrinsic
subtypes was assessed by the change in log likelihood ratio
v2, between a model containing only clinical variables
(age, T-stage, N-stage), and a model including clinical
variables and (surrogate) subtype information. To assess
concordance between PAM50 and the surrogate intrinsic
subtypes cross-tables were presented and kappa values
were calculated. All analyses were performed in SPSS
17.0.
Results
Patient and tumor characteristics
In this study we show data of all breast cancer patients who
received neoadjuvant chemotherapy in a single institution.
Since the start of the neoadjuvant program in 2004, 560
patients completed neoadjuvant treatment and had surgery.
From a subset of 247 patients, gene expression data was
available and PAM50 intrinsic subtypes were determined.
Table 1 shows the different definitions of breast cancer
subtyping as well as the number of cases per group. We
subsequently show the following subtype classifications:
IHC-based classification, PAM50 gene expression subtype,
surrogate intrinsic subtype based on Ki67, surrogate intrin-
sic subtype based on grade, and the endocrine responsive-
ness. Patient and tumor characteristics are presented in
Table 2. Note that for the TN and HER2? samples, the
surrogate intrinsic subtypes completely overlap with the
IHC-based classification. The concept of endocrine
responsiveness was only developed for the ER?/HER2-
tumors, so it is only shown for this group.
Response for the surrogate intrinsic subtypes
We assessed response to neoadjuvant chemotherapy for the
different subtype classifications. pCR rates are shown in
Table 3 for the IHC-based subtyping, PAM50 subtyping, the
surrogate intrinsic subtype definitions, based on both Ki67
staining and histological grade, and endocrine responsive-
ness. For the TN and HER2? tumors, the surrogate intrinsic
subtypes are identical to the clinical IHC-based subtypes, so
the response rates for surrogate subtypes are only shown for
the ER?/HER2- tumors. In this subgroup the various
classifications are meant to select a chemotherapy-sensitive
and a chemotherapy-resistant group. Therefore, we focus in
the rest of this study mainly on the ER?/HER2- group. The
surrogate intrinsic subtype based on grade could divide this
subgroup in a Luminal B/HER2- subgroup with limited
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response to chemotherapy (14.6 % pCR), and the Luminal A
group with almost no pCRs (2.3 % pCR) (p = 0.002). The
PAM50 gene expression based subtype, the surrogate
intrinsic subtype based on Ki67 and endocrine responsive-
ness did not differentiate ER?/HER2- tumors in groups
with significantly different chemotherapy responses.
For the ER?/HER2- tumors, we computed multivariate
models to assess if the subtypes have predictive power in
assessing chemotherapy response. We tested four different
models, one employing PAM50, one employing Ki67, one
employing grade, and one employing endocrine respon-
siveness, as these variables are used to define a Luminal A
and Luminal B tumor group. Age, T-stage, and N-stage
were included as covariates. In the model including grade
as a variable, tumors with grade 3 tumors had a higher
probability of achieving a pCR than grade 1 or 2 tumors
(OR = 6.38, p = 0.004). PAM50, Ki67 and endocrine
responsiveness were not associated with pCR rates in a
multivariate model (Table 4). By computing the change in
log likelihood v2 between a model with only clinical
covariates (age, T-stage, and N-stage) and a model
including both clinical covariates and the subtype, we can
compare the fit of the models. Higher values indicate more
added predictive information. The model, including grade,
adds the most information in predicting pCR rates.
Survival analysis
To assess if the surrogate intrinsic subtypes can discriminate
tumors with different survival, Kaplan–Meier curves for
recurrence free survival (Fig. 1) were computed, for IHC,
PAM50, surrogate subtypes (one based on Ki67 and one
based on grade), and for endocrine responsiveness. For the
surrogate definitions and for endocrine responsiveness, we
only show the curves for the ER?/HER2-, as the triple
negative and HER2? subtypes are similar in the surrogate
subtype definitions to the IHC-subtypes. Indeed, the differ-
ent subtypes differentiated the tumors in classes with distinct
relapse free survival (Fig. 1a–e). As expected, the triple
negative or basal groups had the worst survival. Luminal A
tumors had the best survival. From the surrogate definitions,
the definition based on grade had the lowest p value, indi-
cating that the grade was most strongly associated with
survival. We should note that our data are preliminary, as
median follow-up time was only 29 months (range 2–82),
with 169 patients with a follow-up of less than 2 years. This
is very limited, especially for the Luminal subtypes, which
have mostly late recurrences between 5 and 10 years after
treatment. We performed Cox regression analysis to deter-
mine if the surrogate definitions are still predicting survival
when we correct for age, T-stage, and N-stage. Table 5
shows that the definition based on grade resulted in the best
predictor, with the lowest p value and the highest hazard
ratio. Patients with a Luminal B/HER2- surrogate intrinsic
subtype (based on grade) have a five times higher chance on
a recurrence than patients with a Luminal A subtype tumor
within the first years after surgery (HR = 5.3, p = 0.002).
Also, PAM50 based subtypes and endocrine responsiveness
Table 1 Subtype definitions and numbers per subtype in this study




















Luminal A 81 32.8
Luminal B 49 19.8
Normal 26 10.5







Luminal A ER?, HER2-, Ki67 \ 14 % 179 32.0
Luminal B/HER2- ER?, HER2-, Ki67 C 14 % 73 13.0
Luminal B/HER2? HER2?, ER? c 67 12.0
ND 33 5.9







Luminal A ER?, HER2-, grade 1/2 213 38.0
Luminal B/HER2- ER?, HER2-,
grade 3
48 8.6










ER % and PR % C 50 % 144 50.2
ND 1 0.3
a The PAM50 classification was determined for 247 tumors for which we
had gene expression data
b The endocrine responsiveness is only shown for the ER?/HER2-
tumors
c These subtypes are the same as the immunohistochemical subtypes
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are significantly associated with recurrence free survival
(HR = 9.65, p = 0.02 for PAM50 and HR = 4.81,
p = 0.01 for endocrine responsiveness, respectively). When
we consider the change in log likelihood ratio v2, both grade
and endocrine responsiveness add the most predictive
information, followed by PAM50 based subtypes.
Discussion
In this study, we collected data from 560 patients in a
single cancer center who took part in an ongoing neoad-
juvant chemotherapy program. For 247 patients gene
expression data were available. We investigated if different
intrinsic subtype definitions could help to predict neoad-
juvant chemotherapy benefit in breast cancer. Subsequently
we compared IHC-based subtypes, gene expression based
PAM50 subtypes, surrogate intrinsic subtypes both based
on Ki67 and on grade and endocrine responsiveness. The
surrogate intrinsic subtyping was identical to the IHC
subtypes for the basal and the HER2-positive tumors.
Clinically, the surrogate intrinsic subtypes have been sug-
gested to be mainly important to divide the clinical ER?/
HER2- tumors in classes with different prognoses and
chemotherapy responses. In our series, histological grade
had the best predictive power. We therefore prefer to
continue the use of the conventional IHC-subtyping based
on hormone receptors, HER2 and histological grade rather
than the ‘‘surrogate intrinsic subtype’’ classification, at
least in the setting of neoadjuvant chemotherapy.
Our results are in line with a recent study by Von
Minckwitz et al. [4], as we both show that subtypes based
on grade can differentiate tumors with different chemo-
therapy sensitivity. However, von Minckwitz et al. did not
compare the different subtype definitions. By comparing
the association between the different subtype classifica-
tions and chemotherapy response, we see that grade is
better than Ki67 or endocrine responsiveness in identifying
groups of tumors with different chemotherapy response in
this dataset. A recent review by the Breast International
Group and North American Breast Cancer Group [11]
recommends to use surrogate intrinsic subtypes based on
Ki67, but acknowledge that the definition of low and high
proliferation might be subject to change. Our study con-
tradicts this recommendation, as we see that grade has
more predictive power than Ki67. We should note that the
number of responding ER?/HER2- tumors is small in our
dataset, and a definite conclusion should therefore be based
on larger datasets.
Breast cancer intrinsic subtypes have been subjected to
many studies and a variety of classifications exist [1, 10,
12–15]. Different classifications are said to lead to the
same molecular classification of breast cancer in the five
subtypes, however, a recent study by Weigelt et al. [16]
contradicts this assumption. In that study the agreement
between three different types of gene expression based
intrinsic subtyping methods was assessed. Only the basal
Table 2 Patient and tumor characteristics
n %
Age
\50 years 328 58.6
























\14 % 191 34.1
C14 % 148 26.4
ND 221 39.5
Chemotherapy
6 9 AC 310 55.4
6 9 DC 22 3.9
3 9 AC, 3 9 DC 119 21.3
Trastuzumab based 109 19.5
Local Recurrence




No pCR 440 78.6
pCR 120 21.4
ND not determined, AC doxorubicin/cyclophosphamide, DC doce-
taxel/capecitabine, pCR pathological complete remission
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subtype showed a good agreement between classifiers,
whereas for the other subtypes the agreement was fair to
moderate. Consequently, the authors conclude that it is too
early to use the intrinsic subtypes into clinical practice. We
determined the concordance between the PAM50 based
classification, immunohistochemical subtypes, surrogate
intrinsic subtypes, and endocrine sensitivity (Supplemen-
tary Table 1). In line with Weigelt’s findings, the concor-
dance for the basal likes was good, but modest for the other
subtypes.
This study has several limitations. First, there were
missing values for Ki67 staining and for grade. We used
both to differentiate between Luminal A and Luminal
B/HER2- tumors [2]. As seen in Supplemental Fig. 2,
there is a correlation between Ki67 staining and grade, but
it is far from perfect. Both Ki67 staining and histological
grade determination have their pros and cons. Cheang et al.
determined a cut-off percentage of positive nuclei to
classify a sample as either Luminal A or Luminal B, and
found that the false positive and false negative rates were
both 25 % [7]. Also, the cut-off of Cheang et al. is based on
patients treated in the adjuvant setting, which is different
from the neoadjuvant setting. It has been recommended
that each laboratory establishes its own optimal value. In
our dataset, an optimal cut-off is between 10 and 15 %, we
therefore kept to use the 14 % cut-off as was assessed by
Viale and co-authors [17–19]. Apart from this, the supe-
riority of grade over Ki67 is perhaps not surprising. In
addition to proliferative activity, grade also incorporates
two other characteristics of the tumor: the degree of tubule
formation and the degree of nuclear polymorphism, both
which could correlate with chemosensitivity. A second
limitation is that survival data were derived from a limited
follow-up period, as the study included many patients from
recent years. The median follow-up was 29 months (range
2–82). This is relatively brief for the luminal subtypes,
which are subjected to late recurrences which may occur up
to 15 years or later after the diagnosis of their primary
tumor [20]. Strong points of this study are that we have a
large, single institution dataset. For half of patients we had
both gene expression and IHC data. HER2 status was
checked by CISH in tumors with intermediate IHC scores.
Further, all pathology data was reviewed by the same
expert breast pathologist. Also, chemotherapy regimens
were the same for most patients: the large majority of the
HER2- tumors were treated by six courses of anthracyline
based or anthracyclin-taxane-based chemotherapy and the
HER2? tumors received trastuzumab in combination with
carboplatin and paclitaxel.
Table 3 Response according to different subtype classifications
% Ratio p valuea





PAM50 (n = 247)
Basal 41.7 20/48
HER2-enriched 48.8 21/43
Luminal A 4.9 4/81
Luminal B 8.2 4/49 0.47
Normal 19.2 5/26
Surrogate intrinsic (Ki67) (n = 252)
Luminal A 3.9 7/179
Luminal B/HER2- 5.5 4/73 0.74
Surrogate intrinsic (grade) (n = 261)
Luminal A 2.3 5/213
Luminal B/HER2- 14.6 7/48 0.002
Endocrine responsiveness (n = 286)
Highly endocrine sensitive 3.5 5/142
Incompletely endocrine sensitive 6.3 9/144 0.41
a p values are shown for the comparison between Luminal A versus
Luminal B tumors or highly versus incompletely endocrine sensitive
tumors
Table 4 Multivariate analysis of pCR in ER?/HER2- tumors
OR 95 % CI p value LR-v2
Model based on PAM50
Age (C50 vs. \50 years) 0.62 0.06–6.32 0.68
T-stage (T3/4 vs. \T1/2) 0.83 0.08–8.93 0.88
N-stage (N? vs. N-) 0.67 0.07–6.75 0.73
PAM50 (Luminal B vs.
Luminal A)
1.74 0.22–13.64 0.60 0.28
Model based on Ki67 %
Age (C50 vs. \50 years) 0.12 0.01–0.95 0.04
T-stage (T3/4 vs. \T1/2) 0.65 0.28–1.51 0.32
N-stage (N? vs. N-) 1.07 0.52–2.2 0.86
Ki67 % (C14 % vs. \14 %) 1.12 0.31–4.05 0.87 -0.32
Model based on grade
Age (C50 vs. \50 years) 0.12 0.01–0.95 0.04
T-stage (T3/4 vs. \T1/2) 0.75 0.3–1.85 0.53
N-stage (N? vs. N-) 0.94 0.53–1.66 0.82
Grade (3 vs. 1/2) 6.36 1.82–22.3 0.004 9.08
Model based on endocrine responsiveness
Age (C50 vs. \50 years) 0.19 0.04–0.9 0.04
T-stage (T3/4 vs. \T1/2) 0.70 0.33–1.48 0.35
N-stage (N? vs. N-) 0.92 0.62–1.36 0.67
Endocrine responsive
(incomplete vs. highly)
2.07 0.66–6.44 0.21 -0.32
Values in bold indicate significant p values (p \ 0.05) and associated
best fit models
LR-v2, change in log likelihood v2
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In conclusion, our findings do not make a strong case for
the ‘‘surrogate intrinsic subtype’’ terminology. For the
ER?/HER2- tumors, the routine determination of IHC
positivity for the estrogen receptor, HER2 in situ hybrid-
ization and grade yield the best separation of prognostic—
in terms of RFS—and predictive—in terms of pCR rates—
subgroups. For the other surrogate subtypes, ER and HER2
define the surrogate subtype (by definition). As the con-
cordance between surrogate intrinsic subtype and PAM50
subtype is far from perfect, the terminology appears














































































































































Fig. 1 RFS curves for subsequently the traditional IHC subtypes (log
rank p value = 0.0002) (a), the PAM50 subtypes (log rank
p value = 0.003) (b), the surrogate intrinsic subtypes-Ki67 (log rank
p = 0.19) (c), the surrogate intrinsic subtypes-grade (log rank
p = 0.003) (d), and endocrine sensitivity (log rank p = 0.0067) (e)
Breast Cancer Res Treat (2013) 140:63–71 69
123
Acknowledgments This study was carried out within the frame-
work of CTMM, the Center for Translational Molecular Medicine
(www.ctmm.nl), Project Breast CARE (030-104).
Conflict of interest The authors declare no conflicts of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression
patterns of breast carcinomas distinguish tumor subclasses with
clinical implications. Proc Natl Acad Sci USA 98:10869–10874
2. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for
subtypes–dealing with the diversity of breast cancer: highlights of
the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747
3. Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and
promise: highlights of the international expert consensus on the
primary therapy of early breast cancer 2007. Ann Oncol
18:1133–1144
4. von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition
and impact of pathologic complete response on prognosis after
neoadjuvant chemotherapy in various intrinsic breast cancer
subtypes. J Clin Oncol 30:1796–1804
5. Brouckaert O, Laenen A, Vanderhaegen J et al (2012) Applying
the 2011 St Gallen panel of prognostic markers on a large single
hospital cohort of consecutively treated primary operable breast
cancers. Ann Oncol 23(10):2578–2584
6. Loo CE, Straver ME, Rodenhuis S et al (2011) Magnetic reso-
nance imaging response monitoring of breast cancer during
neoadjuvant chemotherapy: relevance of breast cancer subtype.
J Clin Oncol 29:660–666
7. Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2
status, and prognosis of patients with luminal B breast cancer.
J Natl Cancer Inst 101:736–750
8. Colleoni M, Bagnardi V, Rotmensz N et al (2009) Increasing
steroid hormone receptors expression defines breast cancer sub-
types non responsive to preoperative chemotherapy. Breast
Cancer Res Treat 116:359–369
9. Hannemann J, Oosterkamp HM, Bosch CA et al (2005) Changes
in gene expression associated with response to neoadjuvant
chemotherapy in breast cancer. J Clin Oncol 23:3331–3342
10. Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk
predictor of breast cancer based on intrinsic subtypes. J Clin
Oncol 27:1160–1167
11. Fumagalli D, Bedard PL, Nahleh Z et al (2012) A common
language in neoadjuvant breast cancer clinical trials: proposals
for standard definitions and endpoints. Lancet Oncol 13:e240–
e248
12. Haibe-Kains B, Desmedt C, Loi S et al (2012) A three-gene
model to robustly identify breast cancer molecular subtypes.
J Natl Cancer Inst 104:311–325
13. Hu Z, Fan C, Oh DS et al (2006) The molecular portraits of breast
tumors are conserved across microarray platforms. BMC
Genomics 7:96
14. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of
human breast tumours. Nature 406:747–752
15. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation
of breast tumor subtypes in independent gene expression data
sets. Proc Natl Acad Sci USA 100:8418–8423
16. Weigelt B, Mackay A, A’hern R et al (2010) Breast cancer
molecular profiling with single sample predictors: a retrospective
analysis. Lancet Oncol 11:339–349
Table 5 Multivariate cox
proportional hazard analysis of
the risk of recurrence
(recurrence free survival) in
ER?/HER2- tumors
Values in bold indicate
significant p values (p \ 0.05)
and associated best fit models
HR 95 % CI p-value LR-v2
Model based on PAM50
Age (C50 vs. \50 years) 1.81 0.38–8.62 0.46
T-stage (T3/4 vs. \T1/2) 1.46 0.31–6.84 0.63
N-stage (N? vs. N-) 1.13 0.09–14.12 0.92
PAM50 (Luminal B vs. Luminal A) 9.65 1.36–68.4 0.02 8.23
Model based on Ki67 %
Age (C50 vs. \50 years) 2.94 0.86–10.06 0.09
T-stage (T3/4 vs. \T1/2) 1.23 0.48–3.19 0.66
N-stage (N? vs. N-) 1.40 0.36–5.47 0.63
Ki67 % (C14 % vs. \14 %) 3.32 0.82–13.45 0.09 0.11
Model based on grade
Age (C50 vs. \50 years) 2.29 0.78–6.7 0.13
T-stage (T3/4 vs. \T1/2) 2.09 0.88–4.94 0.09
N-stage (N? vs. N-) 1.10 0.34–3.53 0.87
Grade (3 vs. 1/2) 5.30 1.82–15.39 0.002 9.16
Model based on endocrine responsiveness
Age (C50 vs. \50 years) 2.34 0.85–6.46 0.10
T-stage (T3/4 vs. \T1/2) 1.86 0.89–3.87 0.10
N-stage (N? vs. N-) 1.04 0.41–2.64 0.94
Endocrine responsive (incomplete vs. highly) 4.81 1.36–17.07 0.01 9.06
70 Breast Cancer Res Treat (2013) 140:63–71
123
17. Viale G, Regan MM, Mastropasqua MG et al (2008) Predictive
value of tumor Ki-67 expression in two randomized trials of
adjuvant chemoendocrine therapy for node-negative breast can-
cer. J Natl Cancer Inst 100:207–212
18. Goodson WH III, Moore DH, Ljung BM et al (2000) The prog-
nostic value of proliferation indices: a study with in vivo bromo-
deoxyuridine and Ki-67. Breast Cancer Res Treat 59:113–123
19. Liu S, Edgerton SM, Moore DH et al (2001) Measures of cell
turnover (proliferation and apoptosis) and their association with
survival in breast cancer. Clin Cancer Res 7:1716–1723
20. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
(2005) Effects of chemotherapy and hormonal therapy for early
breast cancer on recurrence and 15-year survival: an overview of
the randomised trials. Lancet 365:1687–1717
Breast Cancer Res Treat (2013) 140:63–71 71
123
